Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Recruiting 3Active not recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Tumor-Agnostic 1

Conditions

Lymphoma, Follicular 1Carcinoma 1Burkitt Lymphoma 1

Interventions

Specimen Handling 186pembrolizumab 151Magnetic Resonance Spectroscopy 151Carboplatin 114Biopsy 104Cyclophosphamide 96Cisplatin 88Paclitaxel 79Gemcitabine 71Bevacizumab 68fludarabine 60Nivolumab 58Fluorouracil 51Radiotherapy 49Dexamethasone 47Capecitabine 47Pemetrexed 46Oxaliplatin 44Docetaxel 44Rituximab 43Leucovorin 41Doxorubicin 40venetoclax 39durvalumab 39atezolizumab 39Temozolomide 32Standard of Care 32Radiation 32Cetuximab 32130-nm albumin-bound paclitaxel 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Diphenhydramine × 30 days × Clear all
NCT07570173 2026-05-26

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
340 enrolled
Lymphoid

Burkitt Lymphoma

NCT05977998 2026-05-22

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
Tumor-Agnostic

Carcinoma

NCT06043323 2026-05-06

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

M.D. Anderson Cancer Center

Phase 2 Recruiting
20 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡